Table 3.

Hydralazine Dosing Recommendations for the Indication of Resistant Hypertension

NAT2 Status	Recommendation
Intermediatea or Fastb Acetylator	Predicted to have reduced hydralazine efficacy; consider a 50–100% higher starting dose of hydralazine for patients with resistant hypertension. Limit total daily hydralazine dose to 300 mg daily.
Slow Acetylatorc	Predicated to have increased hydralazine levels, which may lead to increased efficacy and/or adverse effects. Use caution with total daily hydralazine doses of 200 mg or more.

^aIntermediate acetylators have one copy of a reduced functioning allele.

^bFast acetylators have no copies of a reduced functioning allele.

^cSlow acetylators have two copies of a reduced functioning allele.